Charles Retina Institute
Charles Retina Institute
Germantown, Tennessee, United States14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-02 | NCT07449923 | |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Recruiting | Phase 2 / Phase 3 | 2026-10-02 | NCT07440225 | |
| Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting | Phase 3 | 2026-09-28 | NCT03683251 | |
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Geographic Atrophy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, age-related macular degeneration, eye disorder, macular degeneration, nervous system disorder, retinal degeneration, retinal disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 2 | 2026-09-22 | NCT05230537 | |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06668064 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) | diabetic macular edema | Active, not recruiting | Phase 1 | 2026-09-02 | NCT06847854 | |
| A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 4 | 2026-07-31 | NCT06795048 | |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2026-04-29 | NCT06556368 | |
| Data Gathering for A10900 | corneal disorder, eye disorder, glaucoma, ocular hypertension, retinal disorder | Recruiting | Not stated | 2026-02-13 | NCT07149740 | |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 | 2025-10-30 | NCT06116916 | |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | Active, not recruiting | Phase 2 | 2025-10-30 | NCT06116890 | |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-06-17 | NCT06495918 | |
| A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | Not yet recruiting | Phase 3 | 2025-04-06 | NCT06470373 | |
| Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Enrolling by invitation | Phase 2 | 2024-06-17 | NCT03999801 |